Pseudoxanthoma Elasticum is a rare disease, inherited as an autosomal recessive disorder, caused by mutation at ABCC6 gene, encoding for the transporter MRP6 which is mainly expressed in the celular membranes of hepatocytes and renal tubular cells. It is known recently, that ATP is the substrate for MRP6; out of hepatocyte, ATP is degraded by ENPP1 enzyme, rendering inorganic pyrophosphate (PPi), which is a potent inhibitor of tissue calcification. The pathogenesis of the disease relies on the early calcification of elastic fibers; the skin (papules and plaques), retinal Bruch's membrane (neovascularization and blidness) and vascular wall (calcification, intermittent claudicattion, angina pectoris and myocardial infarction) are clinically afected. There are no specific local or systemic treatment that change the natural evolution of the disease. One fluor isotope, 18Na F, has high affinity for calcium and allows the specific assessment of calcium deposition in the tissues. A recent paper showed with only four patients that 18Na F PET/TC is feasible as a measurement of calcification in the skin and in the vesel walls and might be used as a surrogate endpoint in clinical trials. Our goal is the utility of 18Na F PET/TC to assess the progression of the disease and potentially its use to show benefits in clinical trials.
pseudoxantoma elástico
síndrome de Grönblad-Strandberg
calcificación
tomografía por emisión de positrones
TEP
PET
tomografía axial computarizada
TAC
TEP/TAC
TEP/TC
fluoruro de sodio flúor 18
fluoruro sódico flúor 18
18F-NaF
radiofármaco
Acción Estratégica en Salud (AES)
01/01/2017 - 31/12/2019
VALDIVIELSO FELICES, PEDRO
FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD (FIMABIS)
INSTITUTO DE INVESTIGACION BIOMEDICA DE MALAGA (IBIMA)
ANDALUCIA
MALAGA
55,055 €